文献速递前列腺癌

前列腺癌诊断后使用复合维生素与复发风险降低相关:CaPSURE前瞻性队列研究

Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
PubMed 文献 · Eur Urol Oncol · 2025-05-06

该研究基于CaPSURE前瞻性队列,纳入1396例接受根治性前列腺切除术或放疗的非转移性前列腺癌患者,评估诊断后复合维生素使用与复发风险的关系。中位随访4.7年期间发生119例复发事件,当前使用复合维生素与复发风险降低独立相关(调整后HR 0.51,95%CI 0.33-0.78),在Gleason评分≥3+4亚组中关联更强。

要点

  • 前列腺癌诊断后当前使用复合维生素与复发风险降低相关(调整后HR 0.51)。
  • 在Gleason评分≥3+4患者中关联更强(HR 0.27),Gleason 3+3患者中无统计学意义。
  • 该关联为观察性发现,需进一步验证,尚不能据此推荐常规使用。

核心结论

  • 前列腺癌诊断后使用复合维生素与复发风险降低相关,尤其在高级别疾病患者中。
  • 该发现需验证和进一步研究。

研究设计与样本

  • 纵向观察性队列研究,纳入1396例接受根治性前列腺切除术或放疗的非转移性前列腺癌患者。
  • 患者来自CaPSURE研究,入组时间为1999年至2018年。
  • 诊断后复合维生素使用通过问卷确定,调查在诊断后、任何复发前完成。

主要发现

  • 队列中当前使用者858例(62%),既往使用者227例(16%),从不使用者311例(22%)。
  • 中位随访4.7年(四分位距1.9-9.2年)期间发生119例前列腺癌复发事件。
  • 当前使用复合维生素与复发风险降低相关:基本模型HR 0.52(95%CI 0.35-0.78),调整模型HR 0.51(95%CI 0.33-0.78)。
  • 在Gleason评分≥3+4亚组(n=430)中关联更强:HR 0.27(95%CI 0.13-0.55),p<0.001。
  • 在Gleason 3+3亚组(n=966)中关联无统计学意义。

关键数值与推荐

  • 复发定义为生化复发或启动二线治疗。
  • 多变量Cox比例风险回归模型控制社会人口学因素、临床因素和健康行为。

临床怎么用

  • 目前证据不足以推荐前列腺癌患者常规使用复合维生素以预防复发。
  • 与患者讨论复合维生素使用时,应说明其潜在关联但需个体化评估。

局限性

  • 观察性设计无法排除残余混杂。
  • 复合维生素使用为自我报告,可能存在错分。
  • 随访时间有限,事件数较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Multivitamin (MV) use is common among men with prostate cancer (PC). However, data on MV use in relation to the risk of PC recurrence are limited. METHODS: We conducted a longitudinal observational cohort study in 1396 men with nonmetastatic PC who underwent radical prostatectomy (RP) or radiation therapy (RT) and enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study between 1999 and 2018. The primary outcome was PC recurrence, defined as biochemical recurrence or initiation of secondary treatment. Postdiagnostic MV use was ascertained via a questionnaire after diagnosis and before any recurrence. Multivariable Cox proportional-hazards regression models controlled for sociodemographic factors, clinical factors, and health behaviors and were used to calculate adjusted hazards ratios (HRs) and 95% confidence intervals (CIs). KEY FINDINGS AND LIMITATIONS: In the study cohort there were 858 (62%) current MV users, 227 (16%) past MV users, and 311 (22%) never users. We observed 119 PC recurrence events over a median follow-up of 4.7 (interquartile range 1.9-9.2) yrs after survey completion. Current MV use was associated with lower risk of PC recurrence (basic model: HR 0.52, 95% CI 0.35-0.78; adjusted model: HR 0.51, 95% CI 0.33-0.78). In stratified analyses, the inverse association between current MV use and PC recurrence was stronger for men with grade group 2 (Gleason 3 + 4) or greater PC (n = 430; HR 0.27, 95% CI 0.13-0.55; p < 0.001) and was not statistically significant for men with grade group 1 (Gleason 3 + 3) PC (n = 966). CONCLUSIONS AND CLINICAL IMPLICATIONS: MV use after PC diagnosis was associated with lower risk of PC recurrence, particularly in patients with higher-grade disease. This finding warrants validation and further investigation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Shee K, Cedars BE, Wang L, et al. Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Eur Urol Oncol. 2025. PMID: 40335395. doi:10.1016/j.euo.2025.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。